Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford BioTherapeutics Ltd.

www.oxbt.co.uk

Latest From Oxford BioTherapeutics Ltd.

Deal Watch: Millendo Completes Merger With OvaScience, With $85m In Bank For Two Mid-Stage Programs

OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.

Deals Business Strategies

Appointments: Tiziana, Ergomed, Kymab, Crescendo, Ablynx, Axcella and Alexion.

This week's roundup includes CEO appointments by Tiziana and Ergomed and executive appointments by Crescendo Biologics, Ablynx, Alexion and Axcella. In addition to this, Oxford BioTherapeutics and Kymab have announced board appointments.

Appointments BioPharmaceutical

Appointments: EFPIA, Celgene, AcelRx, PureTech Health, Symbiomix, CRISPR Therapeutics and Achaogen

This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.

Appointments

Deals Shaping The Medical Industry, February 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Oxford Genome Sciences (UK) Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oxford BioTherapeutics Ltd.
  • Senior Management
  • Christian Rohlff, PhD, CEO
    Abderrahim Fandi, MD, PhD, CMO
    Scott Sandler, VP, Fin.
  • Contact Info
  • Oxford BioTherapeutics Ltd.
    Phone: (44) 1235 861770
    94a Innovation Dr.
    Milton Park
    Abingdon, OX14 4RZ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register